Strategic growth: Creo Medical CEO on 2024 progress and 2025 outlook

Proactive - Interviews for investors

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford takes Proactive's Stephen Gunnion through the company’s strong performance in 2024 and strategic plans for 2025. Gulliford described 2024 as a year of "robust growth," underpinned by the Speedboat platform and several new product launches. He highlighted progress across Creo Medical's advanced energy suite and noted that these products are “game-changing, innovative” and designed to “dominate advanced energy in every form of therapy for the endoscopist.” Key strategic developments included the sale of a 51% stake in Creo Medical Europe to Micro-Tech, allowing Creo to retain access to its core GI customer base in Europe. Gulliford explained the move also supports co-development and distribution opportunities in markets such as China and the Americas. He also updated viewers on the collaboration with Intuitive involving the MicroBlate Flex device, aimed at treating lung cancer patients. “We delivered the first robotically guided microwave ablation,” he said, noting that commercial rollout is now underway. Operational efficiencies were also discussed, with £5 million in cost savings expected to fully benefit 2025. Looking forward, Creo is targeting 40–50% revenue growth, driven by product innovations and expanding clinical studies across 11 countries. For more company updates and CEO interviews, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications. #CreoMedical #MedicalDevices #AdvancedEnergy #EndoscopyTech #HealthTech #IntuitiveSurgery #LungCancerTreatment #MicroBlateFlex #SpeedboatUltraSlim #ProactiveInvestors #HealthcareInnovation